Cabpirin® Combination Tablet Receives Regulatory Approval in Japan for Treatment of Acid-related Diseases in Patients Needing Low-dose Aspirin|News Releases | Otsuka Pharmaceutical Co., Ltd.

March 25, 2020

Otsuka Pharmaceutical Co., Ltd.


  • Below is a summary English translation provided by Otsuka as a reference. The original and full press release in Japanese was issued by Takeda and Otsuka on March 25.

Otsuka Pharmaceutical Co., Ltd. (Otsuka) and Takeda Pharmaceutical Co., Ltd. (Takeda) announce that approval has been granted by Japan’s Ministry of Health, Labor and Welfare for Cabpirin® Combination Tablets, a combination of the potassium-competitive acid blocker (P-CAB) vonoprazan fumarate and low-dose aspirin that will be co-promoted in Japan by Otsuka and Takeda. Cabpirin was created by Takeda, which will manufacture it.

Cabpirin® Combination Tablets is a once-daily oral formulation containing 100 mg of aspirin and 10 mg of vonoprazan in one tablet. By combining low-dose aspirin with vonoprazan, it is expected that adherence may be improved in patients who need to take both, and that the recurrence of gastric and duodenal ulcers, which are potential side effects of the administration of low-dose aspirin, may be reduced.

Information in this news release was current as of the original release date.

Related:  Otsuka Pharmaceutical and the Japan Kidney Association Form Collaborative Agreement -Aim to identify practical uses of basic research in the kidney field-|News Releases | Otsuka Pharmaceutical Co., Ltd.

Latest Pharmaceutical Business related News Releases

See More News From: